Cure My Disease

Don't miss your cure!

 Log in / Sign up

New targeted pill takes aim at Hard-to-Treat cancers

NCT ID NCT07383506

Recruiting now Disease control Sponsor: Cogent Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 3 times

Summary

This early-stage trial tests a daily oral drug called CGT6297 in 90 adults with advanced solid tumors that have a specific mutation in the PIK3CA gene. The study has two parts: first, finding a safe dose, and then looking for signs that the drug shrinks tumors. It focuses on people with endometrial cancer or certain types of breast cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CGT6297 (a daily oral pill that targets a specific cancer-driving mutation)
What this could lead to
If successful, this could point toward a new treatment option for people with advanced cancers that have a PIK3CA mutation, especially endometrial and breast cancers.
What could go wrong
This is a very early Phase 1 trial with only 90 participants, so the drug may not prove safe or effective. Side effects are unknown, and many early cancer drugs fail to advance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm endometrial cancer endometrium neoplasm hormone receptor-positive breast cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS, ADULT ENDOMETRIAL CANCER HER2-LOW BREAST CANCER HR POSITIVE/HER-2 NEGATIVE BREAST CANCER PIK3CA MUTATIONS

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • HonorHealth Research Institute

    RECRUITING

    Scottsdale, Arizona, 85258, United States

  • NEXT Austin

    RECRUITING

    Austin, Texas, 78758, United States

  • NEXT Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • Washington University School of Medicine - Siteman Cancer Center

    RECRUITING

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.